Abstract
The identification of cutaneous T cell lymphoma (CTCL) biomarkers may serve as a predictor of disease progression and treatment response. The aim of this study was to map potential biomarkers in CTCL plasma. Plasma metabolic perturbations between CTCL cases and healthy individuals were investigated using metabolomics and ultrahigh performance liquid chromatography–quadrupole time-of-flight mass spectrometry (UHPLC-QTOF/MS). Principal component analysis (PCA) of the spectra showed clear metabolic changes between the two groups. Thirty six potential biomarkers associated with CTCL were found. Based on PCA, several biomarkers were determined and further identified by LC/MS/MS analysis. All of these could be potential early markers of CTCL. In addition, we established that heparin as anticoagulant has better pre-treatment results than EDTA with the UHPLC-QTOF/MS approach.
Highlights
Cutaneous T cell lymphoma (CTCL) is the most common primary malignant T cell lymphoma of the skin, presenting as erythema, plaques, tumors or erythroderma
The identification of cutaneous T cell lymphoma (CTCL) biomarkers may serve as a predictor of disease progression and treatment response
Plasma pretreatment Plasma sample collection and handling procedures are critical for successful metabolomics research studies (Yin et al, 2013)
Summary
Cutaneous T cell lymphoma (CTCL) is the most common primary malignant T cell lymphoma of the skin, presenting as erythema, plaques, tumors or erythroderma. The median onset age of CTCL has been reported as 57 years (Kim et al, 2003). A report from China states the median onset age as being 47.5 years before 2000, and 34 years from 2001-2008, showing the onset of CTCL tends to be in the young (Li et al, 2008). Mycosis fungoides is the most frequent type of CTCL, which has an indolent course initiating as erythema, plaques for years and involving lymph nodes or visceral organs as the disease advances. The aberrant expression and function of the transcriptional factors and regulators of signal transduction have been reported in CTCL (Yin et al, 2013). We aim to differentiate the expression of metabolic molecules in CTCL and map the potential biomarkers in CTCL plasma
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Pacific journal of cancer prevention : APJCP
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
